To evaluate the effect of ivermectin in prostate cancer, we analyzed cell viability using MTT assays in AR-positive prostate cancer cell lines, LNCaP, C4-2, and 22RV1, AR-negative prostate cancer cell lines DU145 and PC-3, and nontumorigenic BPH-1 cells and human prostate primary stromal cells from patients with benign prostatic hyperplasia (BPH) [15]. Here, AR is linked to prostate carcinoma.